Effect of the oxytocin antagonist antocin and agonist decomoton on baboon luteal cell production and release of progesterone

OBJECTIVE: To evaluate the effect of oxytocin, its antagonist antocin, and agonist decomoton on baboon luteal cell P secretion. DESIGN: Prospective study. SETTING: Academic department of obstetrics and gynecology in a US medical school. ANIMAL(S): Luteal-phased timed corpora lutea (CL) from a cohort of adult cycling baboons (Papio anubis). INTERVENTION(S): Dispersed luteal cells from luteal phase baboon CL were cultured and treated with nothing (control), oxytocin (4-400 mU), antocin (4-400 microg), oxytocin with antocin, decomoton (4-400 microg), or oxytocin with decomoton. MAIN OUTCOME MEASURE(S): Basal and hCG (10 U)-stimulated P were measured in the incubate. RESULT(S): Basal P secretion did not change significantly with all peptides studied. The hCG-stimulated P secretion was significantly inhibited by oxytocin (4-400 mU), antocin (4-400 microg), and antocin combined with oxytocin, and with oxytocin, decomoton, and decomoton combined with oxytocin. Antocin (-12%) was less inhibitory than oxytocin (-25% to -22%). Antocin combined with oxytocin enhanced the inhibition to -35% to -39%. Decomoton had stronger (not significant) inhibition than oxytocin. Mean inhibition was 28%-35% with all doses of oxytocin, decomoton, or combined together. CONCLUSION(S): Although decomoton, an oxytocin agonist inhibited hCG-stimulated luteal cell P secretion in vitro, antocin also acted like an agonist, rather than an antagonist, in inhibiting P secretion

Baboon corpus luteum: Size and sex steroid secretion throughout the luteal phase

OBJECTIVE: To determine the size of the baboon corpus luteum (CL) and levels of plasma P, 17alpha-hydroxyprogesterone (17-OHP), and E2 in the ovarian vein draining it, the contralateral ovarian vein, and peripheral blood throughout the luteal phase of the menstrual cycle. DESIGN: Prospective study. SETTING: Academic department of obstetrics and gynecology in a US medical school. ANIMAL(S): Corpora lutea from a cohort of 27 adult cycling baboons (Papio anubis). INTERVENTION(S): Timed luteectomy. MAIN OUTCOME MEASURE(S): The authors weighed 166 CL and measured plasma P, 17-OHP, and E(2) in the blood samples obtained at luteectomy. RESULT(S): Early luteal phase corpora lutea weighed 189.1 12.3 mg (mean SEM); their weight significantly increased to 239.4 8.4 mg at mid luteal phase and significantly declined to 188.3 14.0 mg in late luteal phase. Plasma P draining the CL (134.4 20.5 ng/mL in early, 167.4 18.7 ng/mL in mid, and 126.4 23.4 ng/mL in late luteal phase) was significantly higher than that in contralateral ovarian (11.0 1.4 ng/mL) and peripheral plasma (7.1 0.9 ng/mL). Similarly, levels of both plasma 17-OHP (10.9 1.5 to 15.9 2.4 ng/mL) and E2 (1.6 0.2 to 2.6 0.6 ng/mL) draining the CL were significantly higher than those from the contralateral ovary and peripheral blood (17-OHP, 1.1 0.2 ng/mL; E2, 0.2 0.05 ng/mL). CONCLUSION(S): Largest in mid luteal phase, the baboon CL secretes P, 17-OHP, and E2 throughout the luteal phase, with the highest levels seen in the ovarian vein draining the CL in the mid compared with the early and late luteal phases

Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F2alpha in a randomized, double-blind, crossover treatment with placebo, acetaminophen, and ibuprofen in primary dysmenorrhea

OBJECTIVE: The purpose of this study was to compare acetaminophen with ibuprofen for pain relief and menstrual fluid prostaglandin F2alpha (PGF2alpha) suppression in primary dysmenorrhea. STUDY DESIGN: Twelve subjects were randomized to placebo, acetaminophen (1000 mg orally, 4 x daily for 3 days) or ibuprofen (400 mg orally, 4 x daily for 3 days), once during each cycle in a prospective, double-blinded, crossover study. Using preweighed super absorbent tampons, menstrual fluid was collected, extracted, and PGF2alpha radioimmunoassayed. RESULTS: Ten patients completed the study. Ibuprofen (P = .002) and acetaminophen (P = .022) were rated significantly better than placebo. Total menstrual fluid PGF2alpha with placebo was 36.2 + 6.1 microg but were 14.8 + 3.0 microg with ibuprofen (P = .001) and 21.4 + 3.4 microg with acetaminophen (P = .008). PGF2alpha concentrations with placebo were 0.34 + 0.054 microg/mL, with ibuprofen 0.16 + 0.026 microg/mL (P = .001), and with acetaminophen 0.23 + 0.029 microg/mL (P = .016). CONCLUSION: Both ibuprofen and acetaminophen were superior to placebo for pain relief and menstrual fluid PGF2alpha suppression, with ibuprofen being more potent

Differential suppression of menstrual fluid prostaglandin F2a, prostaglandin E2, 6-keto prostaglandin F1a and thromboxane B2 by suprofen in women with primary dysmenorrhea

Eleven women with primary dysmenorrhea completed a randomized, double-blind, placebo-controlled, three-way cross-over study comparing 200 and 400mg suprofen. Menstrual fluid volume did not change. MeanS.E.M. menstrual fluid PGF2a was significantly suppressed from 18.91.9 microg (placebo) to 10.91.7 and 9.32.1 microg with 200 and 400 mg suprofen, respectively (p=\u3c0.005). PGE2 dropped from 7.80.9 to 4.60.8 and 4.61.1 microg (p=\u3c0.05) and TxB2 from 17.54.3 to 7.52.9 and 3.61.3 microg (p=\u3c0.01), respectively. 6-Keto PGF1a was significantly suppressed (2.70.4 to 1.90.5 microg, p=\u3c0.025) with only 400 mg suprofen. Six subjects rated placebo poor and five fair to very good. In contrast, nine rated suprofen excellent to fair while two rated poor. Thus, suprofen was clinically effective but the differential suppression of prostanoids favors 200mg which spares 6-keto PGF1a

Pulsatile oxytocin for induction of labor: a randomized prospective controlled study

Peer Reviewe

ABO blood group in trophoblastic disease

Journal of Obstetrics and Gynaecology of the British Commonwealth7810918-92

Ruptured haemangioma of a gravid uterus

Journal of Obstetrics and Gynaecology of the British Commonwealth795474-47